Idexx Laboratories(DE:IX1)
€634.20+7.00 (+1.12%)
DE:IX1
Idexx Laboratories stock forecast
€634.20
At close:+7.00 (+1.12%)
Idexx Laboratories (IX1) Stock Forecast & Price Target
3 Followers
IX1 Analyst Ratings
Strong Buy
6Buy2Hold0Sell
Based on 8 analysts giving stock ratings to Idexx Laboratories in the past 3 months
IX1 Stock 12 Month Forecast
Average Price Target
€668.12▲(5.35% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is EUR 668.12 with a high forecast of EUR 726.41 and a low forecast of EUR 627.76. The average price target represents a 5.35% change from the last price of EUR 634.20.
Past 12 Months12 Month ForecastJan2026Oct2026
High€726.41
Average€668.12
Low€627.76
Highest Price TargetHighest€726.41Average Price Target€668.12Lowest Price TargetLowest€627.76
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Andrea Alfonso | UBS | €562.30→€627.76 | hold | -1.02%Downside | Assigned | 11/03/26 | ||
| Erin Wright | Morgan Stanley | €721.93→€726.41 | buy | 14.54%Upside | Reiterated | 11/03/26 | ||
| Keith Devas | Jefferies | €632.25→€690.54 | buy | 8.88%Upside | Reiterated | 11/03/26 | ||
| Jonathan Block | Stifel Nicolaus | €605.34→€627.76 | buy | -1.02%Downside | Reiterated | 11/03/26 | ||
| Chris Schott | J.P. Morgan | €695.02→€672.60 | buy | 6.06%Upside | Assigned | 10/16/26 | ||
| Matthew Dellatorre | Goldman Sachs | €663.63 | buy | 4.64%Upside | Initiated | 10/15/26 | ||
| Scott Schoenhaus | KeyBanc | ― | hold | ― | Initiated | 10/12/26 | ||
| Ryan Daniels | William Blair | ― | buy | ― | Reiterated | 10/02/26 | ||
| Michael Ryskin | Bank of America Securities | €591.89→€596.37 | hold | -5.96%Downside | Reiterated | 08/14/26 | ||
| Glen Santangelo | Barclays | €636.73 | buy | 0.40%Upside | Reiterated | 08/11/26 | ||
| Daniel Grosslight | Citi | €582.92→€600.86 | hold | -5.26%Downside | Reiterated | 08/05/26 | ||
| David Westenberg | Piper Sandler | €695.02→€672.60 | hold | 6.06%Upside | Reiterated | 02/09/26 | ||
| Mark Massaro | BTIG | €744.35→€717.44 | buy | 13.13%Upside | Reiterated | 02/03/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Andrea AlfonsoUBS | HoldAssigned€562.30→€627.76 | 11/03/26 | -1.02%Downside | ||
| Erin WrightMorgan Stanley | BuyReiterated€721.93→€726.41 | 11/03/26 | 14.54%Upside | ||
| Keith DevasJefferies | BuyReiterated€632.25→€690.54 | 11/03/26 | 8.88%Upside | ||
| Jonathan BlockStifel Nicolaus | BuyReiterated€605.34→€627.76 | 11/03/26 | -1.02%Downside | ||
| Chris SchottJ.P. Morgan | BuyAssigned€695.02→€672.60 | 10/16/26 | 6.06%Upside | ||
| Matthew DellatorreGoldman Sachs | BuyInitiated€663.63 | 10/15/26 | 4.64%Upside | ||
| Scott SchoenhausKeyBanc | HoldInitiated | 10/12/26 | ― | ||
| Ryan DanielsWilliam Blair | BuyReiterated | 10/02/26 | ― | ||
| Michael RyskinBank of America Securities | HoldReiterated€591.89→€596.37 | 08/14/26 | -5.96%Downside | ||
| Glen SantangeloBarclays | BuyReiterated€636.73 | 08/11/26 | 0.40%Upside | ||
| Daniel GrosslightCiti | HoldReiterated€582.92→€600.86 | 08/05/26 | -5.26%Downside | ||
| David WestenbergPiper Sandler | HoldReiterated€695.02→€672.60 | 02/09/26 | 6.06%Upside | ||
| Mark MassaroBTIG | BuyReiterated€744.35→€717.44 | 02/03/26 | 13.13%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Idexx Laboratories
3 Months
Success Rate8/12 ratings generated profit
67%
Average Return
+5.76%
Copying Ryan Daniels's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.76% per trade.
1 Year
Success Rate32/37 ratings generated profit
86%
Average Return
+27.75%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 86.49% of your transactions generating a profit, with an average return of +27.75% per trade.
2 Years
Success Rate32/37 ratings generated profit
86%
Average Return
+56.86%
Copying Jonathan Block's trades and holding each position for 2 Years would result in 86.49% of your transactions generating a profit, with an average return of +56.86% per trade.
IX1 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 7 | 7 | 8 | 6 |
| Hold | 3 | 5 | 6 | 6 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 9 | 12 | 13 | 14 | 10 |
In the current month, IX1 has received 6 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. IX1 average Analyst price target in the past 3 months is 668.12.
IX1 Financial Forecast
High€3.14
Consensus€2.99
Low€2.92
IX1 Earnings Forecast
Next quarter’s earnings estimate for IX1 is EUR 2.99 with a range of EUR 2.92 to EUR 3.14. The previous quarter’s EPS was EUR 3.59. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€1.06B
Consensus€1.06B
Low€1.06B
IX1 Sales Forecast
Next quarter’s sales forecast for IX1 is EUR 1.06B with a range of EUR 1.06B to EUR 1.06B. The previous quarter’s sales results were EUR 1.09B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
IX1 Stock Forecast FAQ
What is DE:IX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Idexx Laboratories’s 12-month average price target is €668.12.
What is DE:IX1’s upside potential, based on the analysts’ average price target?
Idexx Laboratories has 5.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Idexx Laboratories a Buy, Sell or Hold?
Idexx Laboratories has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
What is Idexx Laboratories’s share price target?
The average share price target for Idexx Laboratories is €668.12. This is based on 8 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €726.41, and the lowest forecast is €627.76. The average share price target represents a 5.35% increase from the current price of €634.2.
What do analysts say about Idexx Laboratories?
Idexx Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of Idexx Laboratories?
To buy shares of DE:IX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
